Jingyang Wang

Jingyang Wang has extensive experience in analytical development within the pharmaceutical industry, notably serving as Executive Director, Analytical Development at Atea Pharmaceuticals, Inc., following roles as Sr. Director and Director in the same field. Prior positions include Associate Director of Analytical Development for Small Molecules at GSK and Senior Manager of Analytical Development for Small Molecules at TESARO, Inc. Additionally, Jingyang Wang has contributed to CMC analytical functions at Boston Biomedical, Inc., and held various scientific roles at Idenix Pharmaceuticals before its acquisition by Merck & Co. in 2014, advancing from Scientist II/I to Principal Scientist in CMC.